Equities

Aurora Spine Corp

ASG:CVE

Aurora Spine Corp

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.26
  • Today's Change0.00 / 0.00%
  • Shares traded40.00k
  • 1 Year change-10.34%
  • Beta0.7214
Data delayed at least 15 minutes, as of Jun 06 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurora Spine Corporation is a designer and manufacturer of medical devices. The Company is engaged in the development and distribution of minimally invasive, interspinous fusion systems and devices. Its product line includes implants, surgical tools and biologics. Its implants include Cervical Products, Thoraco-Lumbar Products, and SI joint products. The surgical tools include Anterior Disc Prep, Posterior Disc Prep and Compass 4D Retractor System. The biologics consist of ZIP Graft and SiLO Si-Fusion. The Company is focused on DEXA technology, which opens up treatment for osteoporotic patients. It offers DEXA-C Cervical Implants Featuring Visual Density Markers, and DEXA -L Standalone Anterior Lumbar Interbody Fusion System.

  • Revenue in CAD (TTM)21.29m
  • Net income in CAD-1.76m
  • Incorporated2013
  • Employees13.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lattice Biologics Ltd2.13m-1.30m4.16m--------1.95-0.0102-0.01020.01680.00111.013.838.70---61.69------28.53---61.08--0.00-1.020.00--12.60---46.52------
SQI Diagnostics Inc3.04m-19.13m6.11m55.00------2.01-0.0483-0.04830.0077-0.0350.2863.233.91---179.74-147.99---264.3310.9748.25-628.52-400.280.1193-3.0324.07--783.5352.95-75.46--42.57--
Evome Medical Technologies Inc64.02m-18.23m7.23m195.00------0.1129-0.2326-0.23260.7664-0.00191.344.8110.07328,282.80-38.29---144.95--34.93---28.47--0.3279-2.421.01--------------
Cloud DX Inc1.95m-9.86m11.69m--------6.01-0.0988-0.09880.0208-0.21380.86991.935.26---440.84------85.82---506.78--0.036-1.77----55.39--2.56------
NuGen Medical Devices Inc354.42k-9.08m19.48m--------54.96-0.0488-0.04880.0019-0.01390.04991.4029.80---127.90---240.95--49.09---2,561.29--0.203-6.251.58--117.51---67.84------
Aurora Spine Corp21.29m-1.76m19.97m13.00--2.90--0.9381-0.0244-0.02440.29270.08951.421.924.09---11.69-16.00-16.45-22.2358.8646.65-8.25-11.761.39-5.800.4195---2.4010.83-11.93--10.36--
Hapbee Technologies Inc1.22m-3.30m21.02m--------17.21-0.0453-0.04530.0144-0.0090.27271.797.50---73.74---404.73--50.84---270.48--0.7541--1.73---47.73--26.20------
Medx Health Corp514.09k-4.28m23.61m--------45.92-0.0211-0.02110.0024-0.03060.51630.795941.92---429.39-653.82----38.9949.55-831.70-736.740.034-1.60-----10.68-15.9510.77------
Data as of Jun 06 2024. Currency figures normalised to Aurora Spine Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.